Keywords: glivec, superior, standard, therapy, first-line, cml, iris

Glivec superior to standard therapy in first-line CML: IRIS study

Article | 17 March 2003

• Print This

Novartis' Glivec/Gleevec (imatinib) should be considered the first-linedrug treatment of choice for patients with newly-diagnosed chronic myeloid leukemia, according ...

Enjoying this article? To continue reading you need to login or subscribe.